The life expectancy of German citizens will rise by six years in 2050, according to data published by the Federal Statistical Office, to 88 years for women and 84 for men. The German Association of Research-Based Pharmaceutical Companies (VFA) welcomed the report which, it argues, demonstrates the value of innovative medicines protected by patents.
Gabriele Doblhammer-Reiter, the director of the Rostock-based Center for the Study of Demographic Change (ZDWA), noted the link between life-expectancy and innovative drug therapies. Prof Doblhammer-Reiter said: "modern treatment methods have a large part in this positive development. Particularly in the area of hypertension, the good supply of medicines contributes substantially to the fact that fewer people die from cardiac arrests and strokes."
Cornelia Yzer, the VFA's chief executive, said: "this [data] shows that hardly any another industry sector makes as central a contribution to the extension of life-expectancy as the research-based pharmaceutical enterprises." She also said that the topic of an aging population is "still to a large extent preoccupied with fear." However, not only are people living longer, but new drugs allow citizens to lead more productive lives for longer, Ms Yzer argues.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze